Human Recombinant Insulin Market Analysis | CMI

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. HUMAN RECOMBINANT INSULIN MARKET ANALYSIS • Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region - Global Forecast to 2026 • The global human recombinant insulin market was valued at US$ 27.4 billion in 2018, and is expected to witness a CAGR of 7.2% over the forecast period (2018 – 2026).

3. Figure 1: Global Human Recombinant Insulin Market Share, By Product Type:

4. Market Drivers • Increasing Investment in Diabetes Research Activities is expected to Boost the Growth of Human Recombinant Insulin Market • Various government and private research organizations are engaged research and development activities for developing advanced treatment in diabetes care to increase the effectiveness of human insulin, reduce diabetes burden, and minimize the risk of diabetes associated disorders such as diabetes-associated blindness, kidney disease, heart attacks, strokes or limb loss. For instance, American Diabetes Association (ADA) invested US$ 807.4 million in more than 4,700 research projects in diabetes research since 1952 till 2017. According to ADA, 2017 review, ADA invested more than US$ 37.4 million for diabetes research in 2017, and supported 371 diabetes related research projects. The European Foundation for the Study of Diabetes (EFSD): a division of European Association for the Study of Diabetes (EASD), provides funding initiatives in all areas of diabetes research. EFSD aims to accelerates and support research in the field of diabetes to introduce innovative diabetic management portfolio. • In September 2017, Biocon Limited: an India-based biopharmaceutical firm received funding from Juvenile Diabetes Research Foundation (JDRF) to study oral insulin drug candidate: Tregopil, to evaluate the safety and tolerability in people suffering with type 1 diabetes. The collaboration between Biocon and JDRF is a part of JDRF's Industry Discovery and Development Partnership (IDDP) programme, through which JDRF provides financial support to Biocon to accelerate research in type 1 diabetes management.

5. Increasing Incidence of Diabetes Worldwide is expected to Drive Growth of the Human Recombinant Insulin Market • Insulin plays a vital role in diabetes management by controlling blood sugar level. Both type 1 and type 2 diabetes people are benefited by maintaining blood sugar levels. Increasing incidence of diabetes is expected to be major factor driving growth of the market in the near future. For instance, according to the World Health Organization (WHO), 2016, an estimated 422 million adults are suffering from diabetes. The major spike in incidence of type 2 diabetes over the last decade is mainly attributed to increasing prevalence of obesity. According to the International Diabetes Federation (IDF) Atlas 2017, global burden of diabetes is affecting more than 425 million people, among which one-third are older than 65 years of age. Moreover, the number of people with diabetes may rise to 629 million in 2045. Furthermore, 352 million with impaired glucose tolerance are at high risk of developing diabetes. Furthermore, continuous increase in incidence rate of diabetes, owing to unhealthy life>

6. Market Restraints • However, high cost of insulin may restrain growth of the market, as patients from low and middle countries are unable to afford it. According to the Pharmaceutical Care Management Association (PCMA) May 2018 report, prices of insulin have increased over 10-fold since 1985 and prices have exhibited significant rise during the last past 10 years (2008 to 2018). According to PCMA, prices for Humulin/Novolin have increased from around US$ 25 per prescription in 1985 to nearly US$ 300 in 2016. Furthermore, prices for long-acting insulins have increased from around US$ 100 per prescription in 2007 to nearly US$ 400 in 2016.

7. Key Players • Key players operating in human recombinant insulin market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd., and Dongbao Enterprise Group Co., Ltd.

8. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Reference : https://www.coherentmarketinsights.com/market-insight/human-recombinant-insulin-market-1797

9. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

10. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

11. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/